

# Medical Drug Clinical Criteria

|                    |   |                          |            |
|--------------------|---|--------------------------|------------|
| <b>Subject:</b>    | Select Clotting Agents for Bleeding Disorders |                          |            |
| <b>Document #:</b> | CC-0149                                       | <b>Publish Date:</b>     | 05/01/2025 |
| <b>Status:</b>     | Revised                                       | <b>Last Review Date:</b> | 03/31/2025 |

## Table of Contents

|                                   |                                  |                            |
|-----------------------------------|----------------------------------|----------------------------|
| <a href="#">Overview</a>          | <a href="#">Coding</a>           | <a href="#">References</a> |
| <a href="#">Clinical criteria</a> | <a href="#">Document history</a> |                            |

## Overview

This document addresses select clotting factor replacement treatments for various hereditary blood disorders. Fibrin products, fibrin sealants and blood products provided by blood banks are not included in this document. Non-bypassing factor products for hemophilia A and hemophilia B, as well as Hemlibra and agents for von Willebrand disease are addressed in other documents.

Factor replacement treatments can be created from blood products (human plasma-derived) and others that are manufactured (recombinant). Replacement therapy may be given on a routine, preventive basis which is also called prophylactic therapy. The infusion of factor replacements given to stop a bleeding episode is called on-demand or episodic therapy.

Products in this document include:

- Anti-inhibitor Coagulant Complex
  - FEIBA
- Coagulation Factor X, Human plasma-derived
  - Coagadex
- Factor VIIa Recombinant
  - Novoseven RT
  - SevenFact
- Factor XIII
  - Factor XIII Human plasma-derived ---Corifact
  - Factor XIII A subunit Recombinant ---Tretten
- Fibrinogen Concentrate
  - Human plasma-derived---RiaSTAP
  - Human fibrinogen ---Fibryga
- Anti-tissue factor pathway inhibitor (anti-TFPI)
  - Hympavzi (marstacimab-hncq)
  - Alhemo (concizumab-mtci)
- Antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA)
  - Qfitlia (fitusiran)

Factor X (FX), also called Stuart-Prower factor, can affect females and males equally. The factor X protein is involved in enzyme activation to help produce blood clots.

Factor XIII (FXIII), also called fibrin stabilizing factor, is considered the rarest factor deficiency, and can affect both genders equally. FXIII is responsible for stabilization of blood clots so that the clot doesn't break down and cause recurrent bleeds. FXIII circulates in plasma as FXIII A-subunits and FXIII B-subunits held together by strong bonds. FXIII A is the active unit in the coagulation cascade, while FXIII B acts as only the carrier molecule for subunit A. FXIII B itself does not provide any activity to correct B-subunit deficiencies.

Fibrinogen deficiencies are caused by a deficiency in factor I and includes three forms – afibrinogenemia (absent fibrinogen), hypofibrinogenemia (low levels of fibrinogen), and dysfibrinogenemia (abnormally functioning fibrinogen). Fibrinogen is normally produced in the liver and circulates in the body to help form clots and prevent bleeding. Factor I deficiencies can affect men and women equally.

Inhibitor development is the most common and a severe complication of factor replacement treatment, developing in approximately 15-20% of people with hemophilia (CDC, 2014). Inhibitors are antibodies to replacement factors which reduce response to factor replacement therapy and may result in need for higher doses of factor products. In addition, the use of other agents, such as bypassing agents, does not replace the missing factor "but go around or (bypass) the factors that are blocked by the inhibitor to help the body form

a normal clot” (CDC, 2014) to control bleeding episodes. The FDA-approved bypassing agents are FEIBA, NovoSeven RT, and SevenFact.

FEIBA, NovoSeven RT, and SevenFact all have black box warnings for thromboembolic events, particularly after high doses and/or in patients with thrombotic risk factors. Monitoring for signs and symptoms of thromboembolic events is recommended.

Qfitlia has a black box warning for thrombotic events and acute and recurrent gallbladder disease. It is recommended to interrupt Qfitlia in patients with a thrombotic event and manage. For individuals with history of symptomatic gallbladder disease, it is recommended that alternative treatments be considered.

## Clinical Criteria

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Coagadex (Human-plasma derived Coagulation Factor X)

Initial requests for Coagadex (Human-plasma derived Coagulation Factor X) may be approved if the following criteria are met:

- I. Individual has a diagnosis of severe or moderate hereditary Factor X deficiency (defined as 5 IU/dL or 5% endogenous Factor X or less) (NHF, Srivastava 2020); **AND**
- II. Individual is using for one of the following:
  - A. Treatment of acute bleeding episodes; **OR**
  - B. Peri-procedural management for surgical, invasive or interventional radiology procedures; **OR**
  - C. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes;

**OR**

- III. Individual has a diagnosis of mild hereditary Factor X deficiency (defined as greater than 5 IU/dL or 5% endogenous Factor X) (NHF, Srivastava 2020); **AND**
- IV. Individual is using for one of the following:
  - A. Treatment of acute bleeding episodes; **OR**
  - B. Peri-procedural management for surgical, invasive or interventional radiology procedures; **OR**
  - C. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes when there is documentation of one of the following:
    1. One or more episodes of spontaneous bleeding into joint; **OR**
    2. One or more episodes severe, life-threatening, of spontaneous bleeding as determined by the prescriber; **OR**
    3. Severe phenotype hemophilia determined by the individual’s risk factors that increase the risk of a clinically significant bleed, including but not limited to, participation in activities likely to cause injury/trauma, procoagulant and anticoagulant protein levels, comorbid conditions affecting functional ability and physical coordination, or history of a clinically significant bleed.

Continuation requests for Coagadex (Human-plasma derived Coagulation Factor X) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hereditary Factor X deficiency; **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

Coagadex (Human-plasma derived Coagulation Factor X) may not be approved for the following:

- I. Individual with severe hereditary Factor X deficiency is using for perioperative management of bleeding in major surgery; **OR**
- II. When the above criteria are not met and for all other indications.

### FEIBA (Anti-inhibitor Coagulant Complex)

Initial requests for FEIBA (Anti-inhibitor Coagulant Complex) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hemophilia A or B with inhibitors to Factor VIII or Factor IX; **AND**
- II. Individual is using for one of the following:
  - A. Treatment of bleeding episodes; **OR**
  - B. Peri-procedural operative management for surgical, invasive, or interventional radiology procedures; **OR**
  - C. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Continuation requests for FEIBA (Anti-inhibitor Coagulant Complex) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hemophilia A or B with inhibitors to Factor VIII or Factor IX; **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

FEIBA (Anti-inhibitor Coagulant Complex) may not be approved for the following:

- I. Individual is using to treat bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation Factor VIII or coagulation Factor IX; **OR**
- II. When the above criteria are not met and for all other indications.

### **NovoSeven RT (Factor VIIa Recombinant)**

Initial requests for NovoSeven RT (Factor VIIa recombinant) may be approved if the following criteria are met:

- I. Individual has one of the following diagnoses:
  - A. Hemophilia A or B with inhibitors to Factor VIII or Factor IX; **OR**
  - B. Acquired hemophilia; **OR**
  - C. Congenital Factor VII deficiency; **AND**
- II. Individual is using for one of the following:
  - A. Individual is using for treatment of bleeding episodes; **OR**
  - B. Individual is using in the prevention of bleeding in surgical interventions or invasive procedures;

**OR**

- III. Individual has a diagnosis of Glanzmann's thrombasthenia; **AND**
- IV. Individual is using for the treatment of bleeding episodes and peri-operative management related to diagnosis; **AND**
- V. Individual has documented refractoriness to platelet transfusions with or without antibodies to platelets.

Continuation requests for NovoSeven RT (Factor VIIa recombinant) may be approved if the following criteria are met:

- I. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes); **AND**
- II. Individual has one of the following diagnoses:
  - A. Hemophilia A or B with inhibitors to Factor VIII or Factor IX; **OR**
  - B. Acquired hemophilia; **OR**
  - C. Congenital Factor VII deficiency; **OR**
  - D. Individual has a diagnosis of Glanzmann's thrombasthenia.

NovoSeven RT (Factor VIIa recombinant) may not be approved when the above criteria are not met and for all other indications.

### **Fibryga (Human fibrinogen)**

Initial requests for Fibryga (Human fibrinogen) may be approved if the following criteria are met:

- I. Individual has a diagnosis of acquired or congenital fibrinogen deficiency (afibrinogenemia or hypofibrinogenemia); **AND**
- II. Individual is using for the treatment of acute bleeding episodes.

Continuation requests for Fibryga (Human fibrinogen) may be approved if the following criteria are met:

- I. Individual has a diagnosis of acquired or congenital fibrinogen deficiency (afibrinogenemia or hypofibrinogenemia); **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

Fibryga (Human fibrinogen) may not be approved for the following:

- I. Individual has a diagnosis of dysfibrinogenemia; **OR**
- II. When the above criteria are not met and for all other indications.

### **RiaSTAP (Human plasma-derived Fibrinogen concentrate)**

Initial requests for RiaSTAP (Human plasma-derived Fibrinogen concentrate) may be approved if the following criteria are met:

- I. Individual has a diagnosis of congenital fibrinogen deficiency (afibrinogenemia or hypofibrinogenemia); **AND**
- II. Individual is using for the treatment of acute bleeding episodes.

Continuation requests for RiaSTAP (Human plasma-derived Fibrinogen concentrate) may be approved if the following criteria are met:

- I. Individual has a diagnosis of congenital fibrinogen deficiency (afibrinogenemia or hypofibrinogenemia); **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

RiaSTAP (Human plasma-derived Fibrinogen concentrate) or Fibryga (Human fibrinogen) may not be approved for the following:

- I. Individual has a diagnosis of dysfibrinogenemia; **OR**
- II. When the above criteria are not met and for all other indications.

### **SevenFact (Factor VIIa Recombinant)**

Initial requests for SevenFact (Factor VIIa Recombinant) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of hemophilia A or B with inhibitors to Factor VIII or Factor IX; **AND**
- III. Individual is using for the treatment and control of bleeding episodes.

Continuation requests for SevenFact (Factor VIIa Recombinant) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hemophilia A or B with inhibitors to Factor VIII or Factor IX; **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

SevenFact (Factor VIIa Recombinant) may not be approved for the following:

- I. Individual is using for the treatment of congenital factor VII deficiency; **OR**
- II. Individual is using to treat bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation Factor VIII or coagulation Factor IX; **OR**
- III. When the above criteria are not met and for all other indications.

### **Tretten or Corifact (Factor XIII)**

Initial requests for Corifact (Human Plasma-derived, Factor XIII) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Factor XIII deficiency; **AND**
- II. Individual is using for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes; **OR**
- III. Individual is using for peri-procedural management for surgical, invasive or interventional radiology procedures.

Initial requests for Tretten (Recombinant Factor XIII A-Subunit) may be approved if the following criteria are met:

- I. Individual has a diagnosis of congenital Factor XIII A-Subunit deficiency; **AND**
- II. Individual is using as routine prophylaxis for bleeding.

Continuation requests for Corifact (Human Plasma-derived, Factor XIII) or Tretten (Recombinant Factor XIII A-Subunit) may be approved if the following criteria are met:

- I. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes); **AND**
- II. Individual has a diagnosis of Factor XIII deficiency; **OR**
- III. Individual has a diagnosis of congenital Factor XIII A-Subunit deficiency;
- IV. .

Corifact (Human Plasma-derived, Factor XIII) may not be approved for the following:

- I. When the above criteria are not met and for all other indications.

Tretten (Recombinant Factor XIII A-Subunit) may not be approved for the following:

- II. Individual with congenital Factor XIII B-subunit deficiency; **OR**
- III. When the above criteria are not met and for all other indications.

## Hympavzi (marstacimab-hncq)

Initial requests for Hympavzi (marstacimab-hncq) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of moderate to severe hemophilia A (defined as 5 International Units per deciliter [1IU/dL to 5IU/dL] or less endogenous Factor VIII) without inhibitors (Rezende 2024); **AND**
- III. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes;

**OR**

- IV. Individual is 12 years of age or older; **AND**
- V. Individual has a diagnosis of moderate to severe hemophilia B (defined as 5 International Units per deciliter [5IU/dL or less endogenous Factor IX) without inhibitors (Rezende 2024); **AND**
- VI. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes;

**OR**

- VII. Individual is 12 years of age or older; **AND**
- VIII. Individual has a diagnosis of mild hemophilia A or B (defined as endogenous Factor VIII or Factor IX less than 40 IU/dL [less than 40%], but greater than 5 IU/dL) without inhibitors (NHF, Srivastava 2020); **AND**
- IX. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; **AND**
- X. Individual has one of the following:
  - A. One or more episodes of spontaneous bleeding into joint; **OR**
  - B. One or more episodes of severe, life-threatening, or spontaneous bleeding as determined by the prescriber; **OR**
  - C. Severe phenotype hemophilia determined by the individual's risk factors that increase the risk of a clinically significant bleed, including but not limited to, participation in activities likely to cause injury/trauma, procoagulant and anticoagulant protein levels, comorbid conditions affecting functional ability and physical coordination, or history of a clinically significant bleed.

Continuation requests for Hympavzi (marstacimab-hncq) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hemophilia A or hemophilia B; **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

Hympavzi (marstacimab-hncq) may not be approved when the above criteria are not met and for all other indications.

## Alhemo (concizumab-mtci)

Initial requests for Alhemo (concizumab-mtci) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of moderate to severe hemophilia A (defined as 5 International Units per deciliter [5 IU/dL] or less endogenous Factor VIII) with inhibitors (Rezende 2024); **AND**
- III. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes;

**OR**

- IV. Individual is 12 years of age or older; **AND**
- V. Individual has a diagnosis of moderate to severe hemophilia B (defined as 5 International Units per deciliter [5 IU/dL or less endogenous Factor IX) with inhibitors (Rezende 2024); **AND**
- VI. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes;

**OR**

- VII. Individual is 12 years of age or older; **AND**
- VIII. Individual has a diagnosis of mild hemophilia A or B (defined as endogenous Factor VIII or Factor IX less than 40 IU/dL [less than 40%] but greater than 5 IU/dL) with inhibitors (NHF, Srivastava 2020); **AND**
- IX. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; **AND**
- X. Individual has one of the following:
  - A. One or more episodes of spontaneous bleeding into joint; **OR**
  - B. One or more episodes of severe, life-threatening, or spontaneous bleeding as determined by the prescriber; **OR**
  - C. Severe phenotype hemophilia determined by the individual's risk factors that increase the risk of a clinically significant bleed, including but not limited to, participation in activities likely to cause injury/trauma, procoagulant and anticoagulant protein levels, comorbid conditions affecting functional ability and physical coordination, or history of a clinically significant bleed.

Continuation requests for Alhemo (concizumab-mtci) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hemophilia A or hemophilia B with inhibitors; **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

Alhemo (concizumab-mtci) may not be approved when the above criteria are not met and for all other indications.

### Qfitlia (fitusiran)

Initial requests for Qfitlia (fitusiran) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of moderate to severe hemophilia A (defined as 5 International Units per deciliter [5IU/dL] or less endogenous Factor VIII) with or without inhibitors (Rezende 2024, Young, Srivastava); **AND**
- III. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes;

#### OR

- IV. Individual is 12 years of age or older; **AND**
- V. Individual has a diagnosis of moderate to severe hemophilia B (defined as 5 International Units per deciliter [5IU/dL] or less endogenous Factor IX) with or without inhibitors (Rezende 2024, Young, Srivastava); **AND**
- VI. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes;

#### OR

- VII. Individual is 12 years of age or older; **AND**
- VIII. Individual has a diagnosis of mild hemophilia A or B (defined as endogenous Factor VIII or Factor IX less than 40 IU/dL [less than 40%] but greater than 5 IU/dL) with or without inhibitors (NHF, Young, Srivastava); **AND**
- IX. Individual is using for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; **AND**
- X. Individual has one of the following:
  - A. One or more episodes of spontaneous bleeding into joint; **OR**
  - B. One or more episodes of severe, life-threatening, or spontaneous bleeding as determined by the prescriber; **OR**
  - C. Severe phenotype hemophilia determined by the individual's risk factors that increase the risk of a clinically significant bleed, including but not limited to, participation in activities likely to cause injury/trauma, procoagulant and anticoagulant protein levels, comorbid conditions affecting functional ability and physical coordination, or history of a clinically significant bleed.

Continuation requests for Qfitlia (fitusiran) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hemophilia A or hemophilia B; **AND**
- II. Individual has had a positive therapeutic response to treatment (for example, reduction in frequency and/or severity of bleeding episodes).

Requests for Qfitlia (fitusiran) may not be approved for the following:

- I. Individual has established hepatic impairment (Child-Pugh A, B, or C); **OR**
- II. When the above criteria are not met and for all other indications.

## Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

### Anti-inhibitor Coagulant Complex (FEIBA)

#### HCPCS

J7198 Anti-inhibitor; per IU [FEIBA]

#### ICD-10 Diagnosis

D66 Hereditary factor VIII deficiency [hemophilia A]  
 D67 Hereditary factor IX deficiency [hemophilia B]  
 Z29.89 Encounter for other specified prophylactic measure

Z79.899 Other long term (current) drug therapy [prophylactic]

#### **Factor VIIa Recombinant (NovoSeven RT)**

##### **HCPCS**

J7189 Factor VIIa (Anti-hemophilic factor, recombinant), (NovoSeven RT), 1 mcg

##### **ICD-10 Diagnosis**

D66 Hereditary factor VIII deficiency [hemophilia A]  
D67 Hereditary factor IX deficiency [hemophilia B]  
D68.2 Hereditary deficiency of other clotting factors  
D68.311 Acquired hemophilia  
D68.318 Hemorrhagic disorder due to intrinsic circulating anticoagulants  
D68.4 Acquired coagulation factor deficiency  
D69.1 Qualitative platelet defects [when specified as Glanzmann's thrombasthenia]  
Z29.89 Encounter for other specified prophylactic measures  
Z79.899 Other long term (current) drug therapy [prophylactic]

#### **Factor VIIa Recombinant (SevenFact)**

##### **HCPCS**

J7212 Factor viia (antihemophilic factor, recombinant)-jncw (Sevenfact), 1 microgram

##### **ICD-10 Diagnosis**

D66 Hereditary factor VIII deficiency [hemophilia A]  
D67 Hereditary factor IX deficiency [hemophilia B]  
D68.2 Hereditary deficiency of other clotting factors  
D68.311 Acquired hemophilia

#### **Factor X (Coagadex)**

##### **HCPCS**

J7175 Injection, factor X, (human), 1 IU [Coagadex]

##### **ICD-10 Diagnosis**

D68.2 Hereditary deficiency of other clotting factors  
D68.8 Other coagulation defects  
D68.9 Coagulation defect, unspecified

#### **Factor XIII (Corifact, Tretten)**

##### **HCPCS**

J7180 Injection, factor XIII (Anti-hemophilic factor, human), 1 IU [Corifact]  
J7181 Injection, factor XIII A-subunit, (recombinant), per IU [Tretten]

##### **ICD-10 Diagnosis**

D68.2 Hereditary deficiency of other clotting factors  
Z29.89 Encounter for other specified prophylactic measure

Z79.899 Other long term (current) drug therapy [prophylactic]

### **Fibrinogen Concentrate, Human plasma-derived (RiaSTAP); Human fibrinogen (Fibryna)**

#### **HCPCS**

J7177 Injection, human fibrinogen concentrate (Fibryga), 1 mg  
J7178 Injection, human fibrinogen concentrate, not otherwise specified, 1 mg [RiaSTAP]

#### **ICD-10 Diagnosis**

D68.2 Hereditary deficiency of other clotting factors

### **Hypavzi (marstacimab-hncg)**

#### **HCPCS**

C9304 Injection, marstacimab-hncq, 0.5 mg [Hypavzi]

#### **ICD-10 Diagnosis**

D66 Hereditary factor VIII deficiency [hemophilia A]  
D67 Hereditary factor IX deficiency [hemophilia B]  
Z29.89 Encounter for other specified prophylactic measure  
Z79.899 Other long term (current) drug therapy [prophylactic]

### **Alhemo (concizumab-mtci)**

#### **HCPCS**

C9399 Unclassified drugs or biologicals [when specified as Alhemo (concizumab-mtci)]  
J3590 Unclassified biologics [when specified as Alhemo (concizumab-mtci)]

#### **ICD-10 Diagnosis**

All diagnosis pend [Alhemo]

### **Qfitlia (fitusiran)**

#### **HCPCS**

C9399 Unclassified drugs or biologicals [when specified as Qfitlia (fitusiran)]  
J3490 Unclassified drugs [when specified as Qfitlia (fitusiran)]

#### **ICD-10 Diagnosis**

All diagnosis pend [Qfitlia]

## **Document History**

Revised: 03/31/2025

Document History:

- 03/31/2025 – Select Review: Add Qfitlia criteria. Coding Reviewed: Added HCPCS NOC C9399, J3490 and all diagnosis pend for Qfitlia.
- 03/25/2025 – Coding update only: Removed ICD-10-CM Z29.8 and replaced with Z29.89 for Hypavzi, Corifact, Tretten, NovoSeven, and FEIBA.
- 02/21/2025 – Select Review: Add Alhemo criteria, clarify diagnosis in Hypavzi step therapy. Coding Reviewed: Updated descriptions for HCPCS J7189, J7177, J7178, J7212. Updated descriptions for HCPCS NOC codes for Hypavzi. Updated descriptions for ICD-10-CM D66 and D67 under SevenFact. Added ICD-10-CM Z29.8 for NovoSeven. Removed ICD-10-CM D68.311 and D68.318 from FEIBA. Removed ICD-10-CM D68.0 and D69.1 from SevenFact. Added HCPCS NOC C9399,

J3590, and all diagnosis pend for Alhemo. Removed HCPCS NOC C9399, J3590 and all diagnosis pend for Hymfavzi, and added HCPCS C9304 effective 4/1/25. Added ICD-10-CM D66, D67, Z29.8 and Z79.899 for Hymfavzi.

- 11/15/2024 – Annual Review: update continuation criteria to include diagnoses, update Coagadex criteria, add acquired fibrinogen deficiency for Fibryga, add Hymfavzi criteria and step. Coding Reviewed: Added HCPCS NOC C9399, J3590, and all diagnosis pend for Hymfavzi.
- 11/17/2023 – Annual Review: No change. Coding Reviewed: No changes.
- 06/12/2023 – Select Review: Update Coagadex for new FDA indication. Coding Reviewed: No changes.
- 11/18/2022 – Annual Review: Update do not approve criteria for Corifact, modify prophylaxis criteria for Coagadex, wording and formatting. Coding Reviewed: No changes.
- 11/19/2021 – Annual Review: Add continuation criteria to all agents. Coding Reviewed: No changes.
- 11/20/2020 – Annual Review: Update Coagadex criteria to allow for prophylactic use in those with mild to moderate disease with severe phenotype hemophilia per guidelines. Add new clinical criteria for SevenFact. Updated references. Wording and formatting changes. Coding Reviewed: Added ICD-10-CM D68.8, D68.9, removed Z79.899 for Coagadex. Added HCPCS J7189, Added ICD-10-CM D66, D67, D68.0, D68.2, D68.311, D69.1 for SevenFact. Effective 1/1/2021 Added HCPCS J7212, Removed J7189 for SevenFact only.
- 11/15/2019 – Annual Review: Create new clinical criteria document for select clotting agents for bleeding disorders (FEIBA, Coagadex, Corifact, NovoSeven RT, Tretten, RiaSTAP, and Fibryna removed from ING-CC-0065). Update Coagadex criteria to remove moderate factor X deficiency from the non-approvable criteria for use in perioperative management of bleeding in major surgery per label. Clarified Coagadex criteria for control and prevention of acute bleeding episodes and replaced with “treatment”. Changed name of Fibryna to Fibryga per manufacturer update. Wording and formatting changes for clarity and consistency. Coding Reviewed. No changes.

## References

1. Centers for Disease Control and Prevention. Hemophilia Facts. Available at: <http://www.cdc.gov/ncbddd/hemophilia/facts.html>.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2025. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2025; Updated periodically.
6. National Hemophilia Foundation (NHF). Available at: <http://www.hemophilia.org/>. Accessed on October 7, 2024.
7. National Hemophilia Foundation (NHF). Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. September 2020. Available at <https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Concerning-Products-Licensed-for-the-Treatment-of-Hemophilia-and-Other-Bleeding-Disorders>. Accessed on October 7, 2024.
8. National Hemophilia Foundation. "MASAC Document #290: MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Selected Disorders of the Coagulation System." *Bleeding Disorders*, 10 Sept. 2019, [www.bleeding.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-290-masac-recommendations-concerning-products-licensed-for-the-treatment-of-hemophilia-and-selected-disorders-of-the-coagulation-system](http://www.bleeding.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-290-masac-recommendations-concerning-products-licensed-for-the-treatment-of-hemophilia-and-selected-disorders-of-the-coagulation-system).
9. "Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors (explorer7)." *ClinicalTrials.gov*, sponsored by Novo Nordisk A/S, 19 Sept. 2024, [clinicaltrials.gov/study/NCT04083781](http://clinicaltrials.gov/study/NCT04083781).
10. "Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8)." *ClinicalTrials.gov*, sponsored by Novo Nordisk A/S, 16 Dec. 2024, [clinicaltrials.gov/study/NCT04082429](http://clinicaltrials.gov/study/NCT04082429).
11. Rezende, Suely M et al. "International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology." *Journal of thrombosis and haemostasis : JTH* vol. 22,9 (2024): 2629-2652. doi:10.1016/j.jtha.2024.05.026
12. Srivastava A, Santagostino E, Dougall A, et al. World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 3<sup>rd</sup> edition. August 2020. Available at <https://onlinelibrary.wiley.com/doi/epdf/10.1111/hae.14046>. Accessed on October 7, 2024.
13. "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B." *ClinicalTrials.gov*, U.S. National Library of Medicine, National Institutes of Health, <https://clinicaltrials.gov/study/NCT03938792#participation-criteria>. Accessed July 5, 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.